World's Best Scientists 2026 revealed!
Christoph Thomssen

Christoph Thomssen

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 79 17376 16327 910 877 500 32079

Christoph Thomssen publications per year

The chart shows the history of publications by Christoph Thomssen between 1988 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Christoph Thomssen published across 39 years, from 1988 to 2026, averaging 15.1 papers a year. Output peaked at 39 publications in 2022. 8 of the 588 publications appeared in the last two years.

No. of publications
10 20 30
Bar chart. Horizontal axis: year, 1988 to 2026. Vertical axis: number of publications, 0 to 39. Peak 39 publications in 2022. 1988: 2 publications 1989: 2 publications 1990: 0 publications 1991: 3 publications 1992: 1 publication 1993: 1 publication 1994: 3 publications 1995: 3 publications 1996: 1 publication 1997: 5 publications 1998: 6 publications 1999: 3 publications 2000: 4 publications 2001: 4 publications 2002: 3 publications 2003: 9 publications 2004: 9 publications 2005: 9 publications 2006: 16 publications 2007: 16 publications 2008: 29 publications 2009: 32 publications 2010: 36 publications 2011: 31 publications 2012: 25 publications 2013: 18 publications 2014: 27 publications 2015: 25 publications 2016: 14 publications 2017: 26 publications 2018: 33 publications 2019: 27 publications 2020: 24 publications 2021: 29 publications 2022: 39 publications 2023: 37 publications 2024: 28 publications 2025: 7 publications 2026: 1 publication
1988 2026

588 publications in total across all disciplines

View publications per year as a table
Christoph Thomssen: publications per year, 1988 to 2026
Year Publications
1988 2
1989 2
1990 0
1991 3
1992 1
1993 1
1994 3
1995 3
1996 1
1997 5
1998 6
1999 3
2000 4
2001 4
2002 3
2003 9
2004 9
2005 9
2006 16
2007 16
2008 29
2009 32
2010 36
2011 31
2012 25
2013 18
2014 27
2015 25
2016 14
2017 26
2018 33
2019 27
2020 24
2021 29
2022 39
2023 37
2024 28
2025 7
2026 1
Total 588
Download as CSV

Christoph Thomssen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christoph Thomssen sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 481–500 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 500 publications — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713 500
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Christoph Thomssen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christoph Thomssen sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 78–79 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891 79
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Christoph Thomssen is affiliated with the University of Göttingen in Germany and has an extensive publication record in the fields of medicine, particularly focusing on oncology and cancer research. Their work spans over 273 publications in medicine and 128 in biochemistry, genetics, and molecular biology. Within these disciplines, key subfields include oncology, cancer research, pulmonary and respiratory medicine, pathology and forensic medicine, and molecular biology.

The main research topics covered by their publications focus on advanced breast cancer therapies, breast cancer treatment studies, HER2/EGFR in cancer research, cancer treatment and pharmacology, breast lesions and carcinomas, cancer immunotherapy and biomarkers, and cancer genomics and diagnostics.

They have contributed several notable papers, including:

  • 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5), 2020, Annals of Oncology
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up, 2021, Journal of Clinical Oncology
  • 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4), 2021, UNC Libraries
  • 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7), 2024, The Breast
  • St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer, 2021, Breast Care

The scientist frequently collaborates with several coauthors, including Volkmar Müller, Peter A. Fasching, Nadia Harbeck, Diana Lüftner, and Tanja Fehm.

Recurring publication venues where their work often appears include:

  • Geburtshilfe und Frauenheilkunde
  • Breast Care
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie
  • Cancer Research
  • Annals of Oncology

Best Publications

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

    Martine J. Piccart-Gebhart;Marion Procter;Brian Leyland-Jones;Aron Goldhirsch

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

    F. Cardoso;A. Costa;L. Norton;E. Senkus

  • Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

    Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

    F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck

  • Clinical impact of the plasminogen activation system in tumor invasion and metastasis : Prognostic relevance and target for therapy

    M Schmitt;N Harbeck;C Thomssen;O Wilhelm

  • 1st International consensus guidelines for advanced breast cancer (ABC 1)

    F. Cardoso;A. Costa;L. Norton;D. Cameron

  • Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study

    Frédéric Amant;Gunter von Minckwitz;Sileny N. Han;Marijke Bontenbal

  • Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

    Jens Huober;Gunter von Minckwitz;Carsten Denkert;Hans Tesch

  • Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

    Valentina Guarneri;David Miles;Nicholas Robert;Véronique Diéras

  • uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies.

    Michael J Duffy;Patricia M McGowan;Nadia Harbeck;Christoph Thomssen

  • St. Gallen 2011: Summary of the Consensus Discussion

    Michael Gnant;Nadia Harbeck;Christoph Thomssen

  • Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study

    Gunter von Minckwitz;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

    J. Huober;J. Huober;P.A. Fasching;P.A. Fasching;M. Barsoum;L. Petruzelka

  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.

    Martine Piccart;Marion Procter;Debora Fumagalli;Evandro de Azambuja

  • Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study

    Volker Moebus;Christian Jackisch;Hans-Joachim Lueck;Andreas du Bois

  • Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients

    Sibylle Loibl;André Schmidt;Oreste Gentilini;Bella Kaufman

  • HER-2/neu Gene Amplification and Response to Paclitaxel in Patients With Metastatic Breast Cancer

    Gottfried E. Konecny;Christoph Thomssen;Hans Joachim Lück;Michael Untch

Frequent Co-Authors

Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Michael Untch
Michael Untch Helios Klinikum Berlin-Buch
Christian Jackisch
Christian Jackisch Breast Cancer Research Foundation
Volkmar Müller
Volkmar Müller Universität Hamburg
Peter A. Fasching
Peter A. Fasching University of Erlangen-Nuremberg
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf
Gunter von Minckwitz
Gunter von Minckwitz University of Ulm
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Jens Huober
Jens Huober Kantonsspital St. Gallen

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a range of related online degrees and healthcare career pathways. Many students choose to expand their career options through programs that offer flexibility and targeted knowledge.

For those interested in healthcare leadership, an accelerated healthcare administration degree allows you to gain vital management skills quickly and efficiently. Similarly, registered nurses may opt for an rn to np bridge program to advance from nursing to nurse practitioner status, often through convenient online classes.

The field of health and wellness is also growing. If you are passionate about nutrition and preventive care, a nutritionist online degree can provide thorough training while fitting into your schedule. For graduate-level advancement, a cahme accredited online mha programs list offers guidance to recognized degrees that can boost your credentials in healthcare administration.

Exploring these related pathways can broaden your expertise and increase your career opportunities in the dynamic world of health and medicine.

Best Scientists Citing Christoph Thomssen

Trending Scientists

Recently Published Articles